This single center prospective study is being conducted to evaluate the safety of the cryoablation for patients with pathologically diagnosed painful bone and soft tissue tumors. Enrollment of 10 patients is planned over the 3-year recruitment period. Patients have related local pain after receiving medications or external radiation therapies will be included in this study. Cryoablation will be percutaneously performed under imaging guidance, and a temperature sensor will be used during treatment as necessary. The primary endpoint is prevalence of severe adverse events within 4 weeks after therapy. The secondary endpoint is effectiveness 4 weeks after the procedure.
|Number of pages||4|
|Journal||Acta Medica Okayama|
|Publication status||Published - 2016|
- Soft tissue and bone tumor
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)